Ram I. Mahato

Dr. Ram I. Mahato
Born	(1963-01-11)January 11, 1963 Janakpurdham, Nepal
Alma mater	University of Nebraska Medical Center, Omaha
Scientific career
Fields	Polymeric Nanomedicine

Ram I. Mahato is a Parke-Davis endowed professor at the Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, United States. ^[1] He served as the chair of this Department from 2013 to 2025. He was Professor of Pharmaceutical Sciences and Biomedical Engineering at the University of Tennessee Health Science Center, Memphis. He was Research Assistant Professor at the University of Utah, Senior Scientist at GeneMedicine Inc and a postdoctoral fellow at the University of Southern California, Washington University in St. Louis, and Kyoto University. He received a PhD in drug delivery from the University of Strathclyde and BS from China Pharmaceutical University. He is a CRS Fellow, AAPS Fellow, Permanent Member of BTSS/NIH Study section (2009–2013), and ASGCT Scientific Advisor (nonviral vectors, 2006–2009).

Research activities

He has expertise in molecular and cell biology, biochemistry, biophysics, polymer chemistry, colloid science, pharmaceutics, and medicine. It allowed him to take a multidisciplinary approach for successful research and training students and post-doctoral fellows. His research is focused on the following areas: (i) micelle and nanoparticulate drug delivery, (ii) oligonucleotides, siRNA, miRNA, shRNA and gene delivery (iii) synthesis of novel polymers, lipopeptides, lipopolymers and cationic lipids (iv) construction of plasmid and adenovirus-based gene and shRNA expression systems. These systems are being tested in various disease areas such as improving islet transplantation to treat type 1 diabetes, cancer (pancreatic, prostate and breast) and liver fibrosis.

Research accomplishments

• Delivery and targeting of oligonucleotide and siRNA-based therapies: contributed extensively on the use of antisense and antigene oligonucleotides as well as siRNA for treating liver fibrosis, diabetes and cancer.
• Cell-based therapeutics: contributed extensively on genetic modification of human islets for improved islet transplantation.
• Polymeric nanomedicines and combination therapy. Contributed extensively on polymeric micellar delivery using novel polymers and combination therapy for treating advanced prostate cancer.
• Cytokine gene therapy: Contributed extensively on the use of interleukin-12 (IL-12), interferon-gamma (IFN-γ), vascular endothelial growth factor (VEGF) and growth hormone gene delivery to tumor and diabetes animal models.
• Design of gene delivery systems: Developed polymer, lipid, lipopolymer and peptide-based systems to deliver and transfect oligonucleotides and genes to specific organs in vivo and different cell lines in vitro.
• Formulation sciences: formulated various small drugs, proteins, oligonucleotides and plasmids for in vitro and in vivo studies.
• Drug delivery and pharmacokinetics: determined the pharmacokinetic profiles of small molecules, proteins, oligonucleotides and genes using mice, rats and rabbits.
• Synthesis: synthesized water-soluble and insoluble lipopolymers, soluble steroidal peptides, cationic lipids, and conjugated galactose, mannose and FITC to polylysine for gene delivery.
• Particulate carrier systems: developed various polymeric nanoparticulate carrier systems.
• Lyophilization: lyophilized anticancer drugs and lipid/plasmid complexes.
• Intracellular trafficking: Investigated the mechanism of cellular uptake and intracellular trafficking of plasmids and oligonucleotides.
• More recently he has worked on the development of novel phosphodiesterase inhibitors for treating alcohol and metabolic-dysfunction associated liver disease (PMID: 38950389 and PMID: 36145643).
• He has also recently published on the role of miRNAs in acute myeloid leukemia (PMID: 39369272).
• His current work on pancreatic cancer has focused on the role of miRNAs (PMID: 33177098) and small molecules as anti-cancer therapies (PMID: 38813771)
• His work on medulloblastoma also focuses on combination therapy of BRD4, PI3K, and Hedgehog inhibitors (PMID: 36599397) as anti-neoplastics and radiosensitizers.

A full list of his published work can be found on Google Scholar https://scholar.google.com/citations?user=IjtzdLQAAAAJ&hl=en&oi=ao

References

1. "Ram I. Mahato". unmc.edu. Retrieved 2015-01-04.